Assetmark Inc. Acquires 1,076 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Assetmark Inc. raised its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 19,382 shares of the company’s stock after acquiring an additional 1,076 shares during the period. Assetmark Inc.’s holdings in Inari Medical were worth $799,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC lifted its position in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares in the last quarter. Covestor Ltd lifted its position in Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Inari Medical during the 2nd quarter worth about $104,000. Institutional investors own 90.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NARI shares. Piper Sandler upped their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. William Blair started coverage on shares of Inari Medical in a report on Thursday, July 25th. They issued an “outperform” rating on the stock. Truist Financial upped their target price on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a report on Tuesday, October 29th. Wells Fargo & Company dropped their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $58.89.

Inari Medical Stock Performance

NARI stock opened at $50.56 on Friday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -37.45 and a beta of 0.96. The firm has a 50-day simple moving average of $45.19 and a two-hundred day simple moving average of $46.94. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13.

Insider Transactions at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00. Following the completion of the transaction, the director now directly owns 561,233 shares of the company’s stock, valued at $28,089,711.65. This trade represents a 6.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 126,000 shares of company stock valued at $5,921,390 in the last 90 days. 10.60% of the stock is currently owned by company insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.